{
    "organizations": [],
    "uuid": "02e0eca21a867dc2bb39e164dfea917a25971bfd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-syndax-pharmaceuticals-announces-c/brief-syndax-pharmaceuticals-announces-clinical-collaboration-to-evaluate-entinostat-in-combination-with-anti-pd-l1-cancer-immunotherapy-in-breast-cancer-idUSFWN1P50BX",
    "ord_in_thread": 0,
    "title": "BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - Syndax Pharmaceuticals Inc:\n* SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER\n* SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP\n* SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO‘S ENTINOSTAT AND GENENTECH‘S ATEZOLIZUMAB\n* SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.\n* SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL\n* SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE‘S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM ",
    "published": "2018-01-10T20:11:00.000+02:00",
    "crawled": "2018-01-11T12:17:55.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "syndax",
        "pharmaceutical",
        "inc",
        "syndax",
        "pharmaceutical",
        "announces",
        "clinical",
        "collaboration",
        "evaluate",
        "entinostat",
        "combination",
        "cancer",
        "immunotherapy",
        "breast",
        "cancer",
        "syndax",
        "pharmaceutical",
        "inc",
        "new",
        "clinical",
        "collaboration",
        "genentech",
        "member",
        "roche",
        "group",
        "syndax",
        "pharmaceutical",
        "co",
        "evaluate",
        "combination",
        "co",
        "entinostat",
        "genentech",
        "atezolizumab",
        "syndax",
        "pharmaceutical",
        "inc",
        "financial",
        "term",
        "agreement",
        "disclosed",
        "syndax",
        "pharmaceutical",
        "inc",
        "genentech",
        "responsible",
        "conducting",
        "trial",
        "syndax",
        "pharmaceutical",
        "inc",
        "trial",
        "conducted",
        "part",
        "morpheus",
        "roche",
        "novel",
        "cancer",
        "immunotherapy",
        "development",
        "platform"
    ]
}